Altered synaptic function is considered one of the first features of Alzheimer disease (AD). Currently, no treatment is available to prevent the dysfunction of excitatory synapses in AD. Identification of the key modulators of synaptopathy is of particular significance in the treatment of AD. We here characterized the pathways leading to synaptopathy in TgCRND8 mice and showed that c-Jun N-terminal kinase (JNK) is activated at the spine prior to the onset of cognitive impairment. The specific inhibition of JNK, with its specific inhibiting peptide D-JNKI1, prevented synaptic dysfunction in TgCRND8 mice. D-JNKI1 avoided both the loss of postsynaptic proteins and glutamate receptors from the postsynaptic density and the reduction in size of excitatory synapses, reverting their dysfunction. This set of data reveals that JNK is a key signaling pathway in AD synaptic injury and that its specific inhibition offers an innovative therapeutic strategy to prevent spine degeneration in AD.

c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo / A. Sclip, A. Tozzi, A. Abaza, D. Cardinetti, I. Colombo, P. Calabresi, M. Salmona, E. Welker, T. Borsello. - In: CELL DEATH & DISEASE. - ISSN 2041-4889. - 5(2014), pp. e1019.1-e1019.9. [10.1038/cddis.2013.559]

c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo

T. Borsello
2014

Abstract

Altered synaptic function is considered one of the first features of Alzheimer disease (AD). Currently, no treatment is available to prevent the dysfunction of excitatory synapses in AD. Identification of the key modulators of synaptopathy is of particular significance in the treatment of AD. We here characterized the pathways leading to synaptopathy in TgCRND8 mice and showed that c-Jun N-terminal kinase (JNK) is activated at the spine prior to the onset of cognitive impairment. The specific inhibition of JNK, with its specific inhibiting peptide D-JNKI1, prevented synaptic dysfunction in TgCRND8 mice. D-JNKI1 avoided both the loss of postsynaptic proteins and glutamate receptors from the postsynaptic density and the reduction in size of excitatory synapses, reverting their dysfunction. This set of data reveals that JNK is a key signaling pathway in AD synaptic injury and that its specific inhibition offers an innovative therapeutic strategy to prevent spine degeneration in AD.
Alzheimer Disease; Animals; Disease Models, Animal; Female; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Transgenic; Peptides; Signal Transduction; Synapses
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
sclip1.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.32 MB
Formato Adobe PDF
2.32 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/347190
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 64
  • ???jsp.display-item.citation.isi??? 64
social impact